Capsule Summary Slidesets

Share

Program Content

Activities

  • HIMALAYA: PRO Analysis
    HIMALAYA: Patient-Reported Outcomes for Patients With Unresectable Hepatocellular Carcinoma Receiving Durvalumab ± Tremelimumab
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2022

    Expires: June 05, 2023

    View Activity
  • HERB: T-DXd for BTC
    HERB: Single-Arm Phase II Trial of Trastuzumab Deruxtecan for Unresectable or Recurrent HER2-Expressing Biliary Tract Cancers
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2022

    Expires: June 08, 2023

    View Activity
  • CheckMate 142: 5-Yr Update
    CheckMate 142: 5-Yr Follow-up With Nivolumab ± Ipilimumab for MSI-H/dMMR Metastatic CRC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2022

    Expires: June 08, 2023

    View Activity
  • TOPAZ-1: PRO Data
    TOPAZ-1: Patient-Reported Outcomes From the Phase III Placebo-Controlled Trial of Durvalumab + Gemcitabine + Cisplatin for Advanced Biliary Tract Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2022

    Expires: June 08, 2023

    View Activity
  • PARADIGM
    PARADIGM: Panitumumab + mFOLFOX6 vs Bevacizumab + mFOLFOX6 as First-line Treatment for mCRC With Wild-Type RAS
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2022

    Expires: June 08, 2023

    View Activity
  • TRIPLETE
    TRIPLETE: Phase III Trial of First-line mFOLFOXIRI + Panitumumab vs mFOLFOX6 + Panitumumab in RAS/BRAF Wild-Type mCRC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2022

    Expires: June 08, 2023

    View Activity
  • CAIRO5
    CAIRO5: FOLFOXIRI + Bevacizumab vs FOLFOX/FOLFIRI + Bevacizumab in Patients With Initially Unresectable Colorectal Liver Metastases and Right-Sided and/or RAS/BRAFV600E-Mutated Primary Tumors
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 10, 2022

    Expires: June 09, 2023

    View Activity
  • CONKO-007: CRT vs CT
    CONKO-007: Chemoradiotherapy vs Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 10, 2022

    Expires: June 09, 2023

    View Activity
  • CheckMate 648: Expanded Analysis
    CheckMate 648: Expanded Analysis of First-line Nivolumab + CT vs Nivolumab/Ipilimumab vs CT in Advanced Esophageal Squamous Cell Carcinoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 13, 2022

    Expires: June 12, 2023

    View Activity
  • Dostarlimab in dMMR Rectal Cancer
    Phase II Study of Dostarlimab in Locally Advanced, Mismatch Repair–Deficient Rectal Cancer
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 14, 2022

    Expires: June 13, 2023

    View Activity

Provided by

ProCE Banner

Supporters

AbbVie

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab